Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at BTIG Research

Key Points

• BTIG Research reaffirmed a "Buy" rating on Ovid with a $4.00 price target implying roughly 62.6% upside, and the consensus analyst rating remains "Buy" with an average target around $4.38.
• Ovid reported a quarterly beat—$0.06 EPS versus a ($0.10) estimate and $0.72M revenue versus $0.06M expected—indicating stronger-than-anticipated near-term results.
• Institutional investors have been adding stakes (72.24% institutional ownership), with RA Capital, Affinity, Eventide and others increasing positions; Ovid is a clinical-stage biotech advancing lead candidate OV101 for Angelman and Fragile X syndromes.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report)'s stock had its "buy" rating reissued by analysts at BTIG Research in a research report issued on Thursday,Benzinga reports. They currently have a $4.00 price target on the stock. BTIG Research's price target would suggest a potential upside of 62.60% from the company's previous close.

OVID has been the subject of several other research reports. Roth Mkm began coverage on shares of Ovid Therapeutics in a research report on Thursday, December 11th. They set a "buy" rating and a $3.00 price target for the company. Wedbush boosted their price objective on shares of Ovid Therapeutics from $5.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, March 20th. Lifesci Capital started coverage on shares of Ovid Therapeutics in a research note on Monday, December 22nd. They set an "outperform" rating and a $4.00 price objective for the company. Wall Street Zen upgraded shares of Ovid Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. Finally, HC Wainwright reissued a "buy" rating and issued a $2.00 target price on shares of Ovid Therapeutics in a research note on Monday, December 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ovid Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $4.38.

Ovid Therapeutics Stock Performance

Shares of OVID stock opened at $2.46 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 8.97 and a current ratio of 8.97. Ovid Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.72. The stock has a 50 day moving average price of $1.77 and a two-hundred day moving average price of $1.60. The company has a market capitalization of $175.18 million, a P/E ratio of -7.94 and a beta of 0.25.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last released its quarterly earnings data on Wednesday, March 18th. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.16. Ovid Therapeutics had a negative return on equity of 23.98% and a negative net margin of 240.11%.The firm had revenue of $0.72 million during the quarter, compared to analyst estimates of $0.06 million. Analysts expect that Ovid Therapeutics will post -0.4 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OVID. RA Capital Management L.P. purchased a new stake in shares of Ovid Therapeutics in the 4th quarter worth about $17,464,000. Affinity Asset Advisors LLC increased its position in shares of Ovid Therapeutics by 169.8% during the fourth quarter. Affinity Asset Advisors LLC now owns 7,150,000 shares of the company's stock valued at $11,654,000 after buying an additional 4,500,000 shares during the period. Eventide Asset Management LLC purchased a new position in shares of Ovid Therapeutics during the fourth quarter valued at about $6,985,000. ADAR1 Capital Management LLC raised its stake in Ovid Therapeutics by 33,256.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 4,285,000 shares of the company's stock worth $6,985,000 after buying an additional 4,272,154 shares in the last quarter. Finally, Federated Hermes Inc. bought a new position in Ovid Therapeutics in the fourth quarter worth about $5,307,000. 72.24% of the stock is currently owned by institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company's lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.